Developing and Qualifying Novel Endpoints
Best practices for identifying, selecting, and developing novel endpoints from technologies have been lacking–until now. CTTI has clarified a pathway for developing novel endpoints from digital health technologies (DHTs) and created recommendations for terminology, data collection, and reporting. Stakeholders can use these resources to develop novel endpoints that:
• Convey an objective and more accurate representation of the patient experience than traditional endpoints.
• Are potentially meaningful to a broader range of stakeholders, including patients and providers
• May help identify unmet patient needs
• Can be used as exploratory endpoints in existing interventional clinical trials & observational cohort studies
Further, CTTI is currently working to create additional recommendations and resources to drive the practical use of novel, digitally derived, functional outcomes as key clinical trial endpoints that can support regulatory labeling claims -- further helping to unlock the opportunities provided by DHTs.
Craig Lipset Pfizer’s head of clinical innovation
“By engaging with experts who have been early champions of mobile technology in trials and combining that with patient insights, CTTI has created practical recommendations and action-oriented tools that have the potential to really accelerate the use of mobile technology in clinical trials. In particular, the use cases provide a realistic pathway for incorporating novel endpoints through technology into clinical development programs. CTTI’s recommendations show we may be closer than previously believed to realizing the benefits of these novel endpoints, creating a sense of urgency to act.”
Valentina Dilda, PhD Director, Experimental Medicine, CHDI Foundation
“As we embark on a two-phase effort to develop a digital battery for use in Huntington Disease trials, we plan to use CTTI’s MCT Novel Endpoints recommendations to guide our work. In doing so, we feel strongly that we can reach our goal more quickly and more efficiently—ultimately, and most importantly, benefiting patients.”
The use of DHTs in clinical trials has increased. This presents a growing opportunity to employ novel endpoints resulting from new measurements, or existing concepts that can use the digital technology to measure outcomes in new or possibly better ways.
While CTTI’s Novel Endpoints project provided recommendations and resources to identify, select, and develop novel endpoints resulting from the use of DHTs, there are currently few examples of novel endpoints derived from a DHT to serve as a standard of evidence to support a labeling claim submitted to regulators. To fill this requirement, CTTI will create recommendations and resources for establishing and using meaningful, DHT-derived novel endpoints for regulatory decision-making.
The Qualification of Novel Endpoints Project, which will build on CTTI’s previous Novel Endpoints project.
As part of this work, CTTI will:
Results from this project will increase the use of meaningful, DHT-derived novel endpoints as key endpoints in clinical trials for regulatory decisions.
The project team will engage in the following actions to support the project objectives:
CTTI convened a multi-stakeholder expert meeting to draft use cases, each developing a particular novel endpoint. Meeting attendees explored the use of accelerometers to measure treatment benefit in clinical trials of heart failure, Parkinson’s disease, and Duchenne muscular dystrophy, and the use of continuous glucose monitors to measure treatment benefit in clinical trials of diabetes. In addition to the four use cases, a meeting summary is available that highlights themes from these discussions.
A set of recommendations were distilled from the meeting findings and related discussions. The recommendations, which are expected to have short-, medium-, and long-term benefits when applied in clinical trials, are grouped into two main sections. The first, which focuses on optimizing the selection of novel endpoints, identifies the following key recommendations:
The second section provides recommendations on practical approaches to developing novel endpoints, including:
These major recommendations are presented in detail, along with complementary materials that include an interactive tool for choosing among possible novel endpoints for development, a quick reference for interacting with regulatory authorities during the process of novel endpoint development, a summary of required steps in novel endpoint development, a plain-language process summary, and detailed, disease area-specific use cases.
The team has also conducted a systematic review of published clinical studies that have employed novel endpoints. The resulting paper will be posted here following publication.
The Qualifications of Novel Endpoints project is expected to yield the following:
|Executive Committee Champion||John Alexander||Duke University|
|Project Manager||Jen Goldsack*||Clinical Trials Transformation Initiative|
|Project Manager||Lindsay Kehoe||Clinical Trials Transformation Initiative|
|Social Science Lead||Brian Perry||Clinical Trials Transformation Initiative|
|Team Leader||Lauren Bataille||The Michael J Fox Foundation for Parkinson's Research|
|Team Leader||Rob DiCicco||GlaxoSmithKline|
|Team Leader||Cheryl Grandinetti||Food and Drug Administration|
|Team Leader||Will Herrington||University of Oxford, CTSU|
|Team Leader||Martin Landray||University of Oxford, CTSU|
|Team Leader||Kaveeta Vasisht||Food and Drug Administration|
|Team Member||Komathi Stem||monARC Bionetworks|
|Team Member||Theresa Strong||Foundation for Prader-Willi Research|
|Team Member||Marc Walton||Johnson & Johnson Pharmaceutical Research and Development|
|Team Member||Ashish Narayan||Feinstein Institute for Medical Research|
|Team Member||Elektra Papodopoulos||Food and Drug Administration|
|Team Member||Nirav Sheth||MC10|
|Team Member||Ken Skodacek||Food and Drug Administration|